Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior
to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa
and IIIb.